Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Exisulind (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 25 Mar 2008 New trial record.